1. Home
  2. RGS vs RLYB Comparison

RGS vs RLYB Comparison

Compare RGS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regis Corporation

RGS

Regis Corporation

HOLD

Current Price

$28.00

Market Cap

72.0M

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$17.50

Market Cap

75.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGS
RLYB
Founded
1922
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.0M
75.9M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
RGS
RLYB
Price
$28.00
$17.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.2K
310.4K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
20.24
N/A
EPS
0.89
N/A
Revenue
$210,134,000.00
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.85
N/A
Revenue Growth
3.52
43.00
52 Week Low
$18.23
$0.27
52 Week High
$31.50
$16.00

Technical Indicators

Market Signals
Indicator
RGS
RLYB
Relative Strength Index (RSI) 51.90 78.59
Support Level $25.95 $0.56
Resistance Level $28.51 N/A
Average True Range (ATR) 1.03 0.71
MACD -0.07 -0.01
Stochastic Oscillator 56.88 98.33

Price Performance

Historical Comparison
RGS
RLYB

About RGS Regis Corporation

Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: